Publication

Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes

Meijers, A., Marmitt, G. G., Ng Wei Siang, K., van der Schaaf, A., Knopf, A. C., Langendijk, J. A. & Both, S., Sep-2020, In : Radiotherapy and Oncology. 150, p. 136-141 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Meijers, A., Marmitt, G. G., Ng Wei Siang, K., van der Schaaf, A., Knopf, A. C., Langendijk, J. A., & Both, S. (2020). Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes. Radiotherapy and Oncology, 150, 136-141. https://doi.org/10.1016/j.radonc.2020.06.027

Author

Meijers, Arturs ; Marmitt, Gabriel Guterres ; Ng Wei Siang, Kelvin ; van der Schaaf, Arjen ; Knopf, Antje C ; Langendijk, Johannes A ; Both, Stefan. / Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes. In: Radiotherapy and Oncology. 2020 ; Vol. 150. pp. 136-141.

Harvard

Meijers, A, Marmitt, GG, Ng Wei Siang, K, van der Schaaf, A, Knopf, AC, Langendijk, JA & Both, S 2020, 'Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes', Radiotherapy and Oncology, vol. 150, pp. 136-141. https://doi.org/10.1016/j.radonc.2020.06.027

Standard

Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes. / Meijers, Arturs; Marmitt, Gabriel Guterres; Ng Wei Siang, Kelvin; van der Schaaf, Arjen; Knopf, Antje C; Langendijk, Johannes A; Both, Stefan.

In: Radiotherapy and Oncology, Vol. 150, 09.2020, p. 136-141.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Meijers A, Marmitt GG, Ng Wei Siang K, van der Schaaf A, Knopf AC, Langendijk JA et al. Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes. Radiotherapy and Oncology. 2020 Sep;150:136-141. https://doi.org/10.1016/j.radonc.2020.06.027


BibTeX

@article{310ad61eece149cf804fa10e06f72ced,
title = "Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes",
abstract = "PURPOSE: Patient specific quality assurance (PSQA) is required to verify the treatment delivery and the dose calculation by the treatment planning system (TPS). The objective of this work is to demonstrate the feasibility to substitute resource consuming measurement based PSQA (PSQAM) by independent dose recalculations (PSQAIDC), and that PSQAIDC results may be interpreted in a clinically relevant manner using normal tissue complication probability (NTCP) and tumor control probability (TCP) models.METHODS AND MATERIALS: A platform for the automatic execution of the two following PSQAIDC workflows was implemented: (i) using the TPS generated plan and (ii) using treatment delivery log files (log-plan). 30 head and neck cancer (HNC) patients were retrospectively investigated. PSQAM results were compared with those from the two PSQAIDC workflows. TCP / NTCP variations between PSQAIDC and the initial TPS dose distributions were investigated. Additionally, for two example patients that showed low passing PSQAM results, eight error scenarios were simulated and verified via measurements and log-plan based calculations. For all error scenarios ΔTCP / NTCP values between the nominal and the log-plan dose were assessed.RESULTS: Results of PSQAM and PSQAIDC from both implemented workflows agree within 2.7% in terms of gamma pass ratios. The verification of simulated error scenarios shows comparable trends between PSQAM and PSQAIDC. Based on the 30 investigated HNC patients, PSQAIDC observed dose deviations translate into a minor variation in NTCP values. As expected, TCP is critically related to observed dose deviations.CONCLUSIONS: We demonstrated a feasibility to substitute PSQAM with PSQAIDC. In addition, we showed that PSQAIDC results can be interpreted in clinically more relevant manner, for instance using TCP / NTCP.",
author = "Arturs Meijers and Marmitt, {Gabriel Guterres} and {Ng Wei Siang}, Kelvin and {van der Schaaf}, Arjen and Knopf, {Antje C} and Langendijk, {Johannes A} and Stefan Both",
note = "Copyright {\textcopyright} 2020. Published by Elsevier B.V.",
year = "2020",
month = sep,
doi = "10.1016/j.radonc.2020.06.027",
language = "English",
volume = "150",
pages = "136--141",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "ELSEVIER IRELAND LTD",

}

RIS

TY - JOUR

T1 - Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes

AU - Meijers, Arturs

AU - Marmitt, Gabriel Guterres

AU - Ng Wei Siang, Kelvin

AU - van der Schaaf, Arjen

AU - Knopf, Antje C

AU - Langendijk, Johannes A

AU - Both, Stefan

N1 - Copyright © 2020. Published by Elsevier B.V.

PY - 2020/9

Y1 - 2020/9

N2 - PURPOSE: Patient specific quality assurance (PSQA) is required to verify the treatment delivery and the dose calculation by the treatment planning system (TPS). The objective of this work is to demonstrate the feasibility to substitute resource consuming measurement based PSQA (PSQAM) by independent dose recalculations (PSQAIDC), and that PSQAIDC results may be interpreted in a clinically relevant manner using normal tissue complication probability (NTCP) and tumor control probability (TCP) models.METHODS AND MATERIALS: A platform for the automatic execution of the two following PSQAIDC workflows was implemented: (i) using the TPS generated plan and (ii) using treatment delivery log files (log-plan). 30 head and neck cancer (HNC) patients were retrospectively investigated. PSQAM results were compared with those from the two PSQAIDC workflows. TCP / NTCP variations between PSQAIDC and the initial TPS dose distributions were investigated. Additionally, for two example patients that showed low passing PSQAM results, eight error scenarios were simulated and verified via measurements and log-plan based calculations. For all error scenarios ΔTCP / NTCP values between the nominal and the log-plan dose were assessed.RESULTS: Results of PSQAM and PSQAIDC from both implemented workflows agree within 2.7% in terms of gamma pass ratios. The verification of simulated error scenarios shows comparable trends between PSQAM and PSQAIDC. Based on the 30 investigated HNC patients, PSQAIDC observed dose deviations translate into a minor variation in NTCP values. As expected, TCP is critically related to observed dose deviations.CONCLUSIONS: We demonstrated a feasibility to substitute PSQAM with PSQAIDC. In addition, we showed that PSQAIDC results can be interpreted in clinically more relevant manner, for instance using TCP / NTCP.

AB - PURPOSE: Patient specific quality assurance (PSQA) is required to verify the treatment delivery and the dose calculation by the treatment planning system (TPS). The objective of this work is to demonstrate the feasibility to substitute resource consuming measurement based PSQA (PSQAM) by independent dose recalculations (PSQAIDC), and that PSQAIDC results may be interpreted in a clinically relevant manner using normal tissue complication probability (NTCP) and tumor control probability (TCP) models.METHODS AND MATERIALS: A platform for the automatic execution of the two following PSQAIDC workflows was implemented: (i) using the TPS generated plan and (ii) using treatment delivery log files (log-plan). 30 head and neck cancer (HNC) patients were retrospectively investigated. PSQAM results were compared with those from the two PSQAIDC workflows. TCP / NTCP variations between PSQAIDC and the initial TPS dose distributions were investigated. Additionally, for two example patients that showed low passing PSQAM results, eight error scenarios were simulated and verified via measurements and log-plan based calculations. For all error scenarios ΔTCP / NTCP values between the nominal and the log-plan dose were assessed.RESULTS: Results of PSQAM and PSQAIDC from both implemented workflows agree within 2.7% in terms of gamma pass ratios. The verification of simulated error scenarios shows comparable trends between PSQAM and PSQAIDC. Based on the 30 investigated HNC patients, PSQAIDC observed dose deviations translate into a minor variation in NTCP values. As expected, TCP is critically related to observed dose deviations.CONCLUSIONS: We demonstrated a feasibility to substitute PSQAM with PSQAIDC. In addition, we showed that PSQAIDC results can be interpreted in clinically more relevant manner, for instance using TCP / NTCP.

U2 - 10.1016/j.radonc.2020.06.027

DO - 10.1016/j.radonc.2020.06.027

M3 - Article

C2 - 32579999

VL - 150

SP - 136

EP - 141

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

ER -

ID: 128403823